Thermo Fisher Scientific Inc., a Waltham company that makes scientific instruments, said Monday that it has agreed to buy One Lambda for $925 million.
Based in California, One Lambda focuses on transplant diagnostics. One Lambda’s diagnostic tests are used by transplant centers for tissue typing, primarily to determine the compatibility of donors and recipients pre-transplant, and to detect the presence of antibodies that can lead to transplant rejection.
According to Thermo Fisher Scientific’s press release, One Lambda has roughly 320 employees, and the company generated revenue of $182 million in 2011.
The transaction is expected to be completed in the fourth quarter of 2012 and is also expected to be immediately accretive upon close and add $0.09 to $0.11 to Thermo Fisher’s 2013 adjusted earnings per share, the company said.
“With its strong technology platform, high margin profile and good growth prospects, the business is perfectly aligned with our specialty in vitro diagnostics strategy,’’ Thermo Fisher president and chief executive Marc N. Casper said in a statement.
The acquisition would be the seventh announced by Thermo Fisher since May 2011, according to data compiled by Bloomberg News; the company has spent at least $6.8 billion on 27 takeovers in the past five years.
Thermo Fisher also announced that its board of directors has authorized the repurchase of an additional $500 million of shares of its own common stock in the open market or in negotiated transactions.